← Eichor
Study identifier: NCT07677124 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images

Condition: Basal Cell Carcinoma  ·  Sponsor: Istanbul Training and Research Hospital

PhaseN/A
Planned participants2500
Who can joinAll sexes, 0 Years to 100 Years
Healthy volunteersNo

About this study

This retrospective observational study aims to develop and evaluate a convolutional neural network (CNN)-based artificial intelligence model for risk classification and histopathological subtype prediction of basal cell carcinoma (BCC) using clinical and dermoscopic images. Histopathologically confirmed BCC cases from a dermatology archive will be included. The primary objective is to assess the diagnostic performance of the CNN model in classifying BCC as low-risk or high-risk. Secondary objectives include predicting histopathological subtypes and comparing the model's performance with that of dermatology physicians. Histopathological diagnosis will serve as the reference standard. All archived data will be anonymized before analysis.

This description comes directly from the study's public registry record.

Talk to the study team

Tugce Nur Izbudak Kara, MD  ·  +905395976598  ·  eizbudak@icloud.com

Always discuss trial participation with your own doctor first.

Locations (1)

Istanbul Training and Research HospitalIstanbul, Istanbul, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07677124